# A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

> **NCT07140939** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Subcutaneous Fat

## Interventions

- **DRUG:** CBL-514 Injection
- **OTHER:** 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT07140939
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-05
- **Final completion:** 2027-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140939, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT07140939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*